<?xml version="1.0" encoding="UTF-8"?>
<p>In recent years, there has been increasing interest in new vaccines against alternative antigenic targets that can provide more broad, long-lasting protection against seasonal and pandemic influenza viruses [
 <xref rid="RSIF20190879C2" ref-type="bibr">2</xref>,
 <xref rid="RSIF20190879C3" ref-type="bibr">3</xref>]. Several such ‘universal’ influenza vaccines (UIVs) are currently in development (
 <xref rid="RSIF20190879TB1" ref-type="table">table 1</xref>) [
 <xref rid="RSIF20190879C14" ref-type="bibr">14</xref>]; they may offer qualitatively new opportunities for influenza control, raising the prospect of routine vaccination programmes that do not need to be updated as often, while also protecting against novel pandemic viruses. 
</p>
